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Non-Artemisinins 
Chloroquine Angola PQ   tab CR 2/2 (100%) failed 
dissolution assays 
Gaudiano et al. 
(2007) 
Chloroquine Burkina Faso PQ   tab C 24/39 (61%) samples 
failed chemical assays 
Tipke et al. 
(2008) 
Chloroquine Cameroon F, PQ   tab C 6/32 (19%) failed 
assays, 1/32 (3%) 
‘substitution’ & 1/32 




sulphate 136 mg 




Basco et al. 
(1997) 
Chloroquine Cameroon F, PQ   tab C 6/11 (55%) of patients 
had taken chloroquine 
with no API detected, 
1/11 (9%) had taken 
PQ chloroquine 
Basco (2004) 
Chloroquine Cameroon F, PQ   tab C 42/133 (32%) 
counterfeit, 8/133 (6%) 
PQ 
Basco (2004) 
Chloroquine Chad GQ   tab C 3/3 passed all tests WHO (1995) 
Chloroquine Cote d’Ivoire F ‘Nirupquin’ ‘Syncom 
Formulations 
(India)’ 
tab C 113.2% of stated API 
in 1/4 samples. 3/4 
contained correct 
chloroquine content. A 
copy of Nivaquine of 
Aventis 
Legris (2005) 
Chloroquine Gabon GQ   syrup C 0/8 failed chemical 
assays 
WHO (2003) 
Chloroquine Gabon PQ   tab C 5/17 (29%) failed 
content assays & 1/7 
(14%) failed 
dissolution tests  
WHO (2003) 
Chloroquine Ghana PQ   syrup 
 
C 1/20 (5%) failed 
content assays 
WHO (2003) 
Chloroquine Ghana PQ   tab C 12/18 (66.7%) failed 




Chloroquine Guinea F   oral CR Made of aspirin WHO (1995) 
Chloroquine Guinea F ‘Nivaquine’ ‘Rhône Poulenc’ syrup CR No API detected, syrup 




Chloroquine Kenya GQ   tab  C All 13 samples passed 
assays 
Kibwage et al. 
(1999) 
Chloroquine Kenya PQ   tab & 
injection 
C 4/29 (14%) tablet 
samples failed assays. 
The one injection 
sample passed 
Thoithi et al. 
(2002) 
Chloroquine Kenya PQ   Syrup C 2/8 (25%) failed 
content assays 
WHO  (2003) 
Chloroquine Kenya PQ   tab C 3/7 (42.8%) failed 




Chloroquine Madagascar S   tab C 2/8 (25%) défauts de 
fabrication’ 
WHO (1995) 
Chloroquine Mali PQ   syrup C 4/6 (66.7%) failed 
content assays 
WHO (2003) 
Chloroquine Mali PQ   tab C 9/19 (47.3%) failed 
content assays and 1/19 
(5.2%) failed 
dissolution tests 
WHO  (2003) 
Chloroquine Mozambique PQ   Syrup C 3/12 (25%) failed 
content assays 
WHO  (2003) 
Chloroquine Mozambique PQ   tab C 3/15 (20%) failed 
content assays & 1/15 
(6.7%) failed 
dissolution tests 
WHO  (2003) 
Chloroquine Nigeria F, PQ   oral C 2/32 (8%)  no API 
detected, 8/32 failed BP 
assays but chloroquine 
detected 








R 9/20 (70%), 20/20 
(100%), 17/18 (94%), 
14/15 (93%) outside 
British Pharmacopeia 
limits 




Nigeria PQ   Syrups 
Tab 
Capsules 
R 8/11 (73%), 15/19 
(93%), 0/1 outside 
British Pharmacopeia 
limits 
Taylor et al. 
(2001) 
Chloroquine Nigeria F    CR Chlorpheniramine sold 
as chloroquine 
Erhun et al. 
(2001) 
Chloroquine Nigeria F ‘Nivaquine’  tab S Fake labels seized Edike (2003) 
Chloroquine Nigeria F ‘Nivaquine’  syrup S Fake labels seized Edike (2003) 
Chloroquine Abeokuta, 
Nigeria 
F, S    C 3/50 (6%) no API 
detected, 16/50 (32%) 
substandard 
Idowu et al. 
(2006) 
Chloroquine Nigeria PQ   tab, syrup and 
injection 
C ‘Over 85% of (14) 
tablet samples 
complied’ with content 
assays and 21% failed 
friability test.  Over 
90% of (13) syrups 
failed content analysis 
(API too high) and 23% 
failed microbial growth 
test. All 5 injections 
failed content analysis. 
All tablets passed 
dissolution/disintegrati
on tests 
Aina et al. 
(2007) 
Chloroquine Nigeria F, PQ   tab C 2/56 failed chemical 




Chloroquine Senegal PQ   tab C 35% failed USP 
monograph tests 








tab CR Made of aspirin Sesay (1988) 
Chloroquine Sudan S   tab Bio 1/5 had significantly 
lower bioavailability 
than the other 4/5 
Mahmoud et al. 
(1994) 
Chloroquine Sudan PQ   tab CR 8% tablets failed 
chemical % API 
analysis and 8% failed 
dissolution tests   
Alfadl et al. 
(2006) 
Chloroquine Sudan PQ   syrup CR Some syrups and 
suspension failed visual 
inspection 
Alfadl et al. 
(2006) 
Chloroquine Sudan GQ   injection CR All passed visual 
inspection and content 
analysis 






Tanzania PQ   tab C 1/3 failed content assay 






phosphate 150 mg 
base 










tab Bio Passed bioequivalence 
testing 




Tanzania GQ 7 brands  tab C Passed content and 
dissolution tests 
Risha et al. 
(2002) 





tab CR 99% API but low 
bioavailability 
Rimoy et al. 
(2002) 
Chloroquine Tanzania PQ 9 brands  tab C All 9 passed content 
assay but 1/9 failed 
dissolution testing. The 
failed sample was sugar 
coated 
Abdi et al. 
(1995) 
Chloroquine Uganda PQ   tab and 
injection 
C Tablets 22/40 (55%) 
and injection 30/48 




Chloroquine Uganda PQ   tab and 
injection 
C Tablets 18/47 (39%) 
and injection 23/45 




Chloroquine Zimbabwe PQ   syrup C 2/15 (13.3%) failed 
content assays 
WHO (2003) 
Chloroquine Zimbabwe PQ   tab C 8/14 (57.1%) failed 
content assays and  
1/14 (7.1%) failed 
dissolution tests 
WHO (2003) 
         
Amodiaquine Burkina Faso GQ   tab C 0/6 samples failed 
chemical assays 
Tipke et al. 
(2008) 
Amodiaquine Ghana PQ   tab C 2/6 (33%) failed TLC 
and/or dissolution tests 
Bate et al. 
(2008) 
Amodiaquine Kenya GQ   tab C One sample of one 
passed assays 
Kibwage et al. 
(1999) 
Amodiaquine Kenya GQ   tab and 
suspension 
C One sample each of 
tablets and suspension 
passed 
Thoithi et al. 
(2002) 
Amodiaquine Kenya PQ   tab 
syrup 
R 11/29 (38%) tablet 
samples & 7/23 (30%) 
syrups failed content 
and/or dissolution tests 
Amin et al. 
(2005) 
Amodiaquine Kenya PQ   tab C 4/8 (50%) failed TLC 
and/or dissolution tests 
Bate et al. 
(2008) 
Amodiaquine Nigeria PQ   tab C 1/4 (25%) failed TLC 
and/or dissolution tests 
Bate et al. 
(2008) 




Smine et al. 
(2002) 
Amodiaquine Tanzania S ‘Emoquin’  ‘Made in Kenya’ tab C 2 (both ‘Emoquin’)/15 
(13%) failed  
dissolution tests 
Minzi et al. 
(2003) 
Amodiaquine Tanzania PQ   tab C 6/100 failed chemical 
tests 
Kaur et al. 
(2008) 
Amodiaquine Tanzania PQ   tab C 2/2 (100%) failed TLC 
and/or dissolution tests 
Bate et al. 
(2008) 
Amodiaquine Uganda PQ   tab C 5/9 (56%) failed TLC 
and/or dissolution tests 
Bate et al. 
(2008) 
Amodiaquine Nigeria PQ   tabs R 1/5 failed dissolution 
tests 
Odunfa et al. 
(2009) 
         
Primaquine 
phosphate 
Namibia PQ   tab CR Peace Corp volunteer 
contracted P. vivax 
during prophylaxis with 
primaquine containing 
12mg/tablet, as 
opposed to genuine 
26.3mg 
Kron (1996) 








Wolff et al. 
(2003), Anon 
(2003a), 
Cockburn et al. 
(2005) 
Halofantrine Nigeria F ‘Halfan’  tab CR Fake labels seized Edike (2003) 
Halofantrine Nigeria F ‘Halfan’  tab CR Smuggled amongst 




Halofantrine Tanzania F ‘Halfan’  tab CR 2005, Counterfeiters 
extended shelf life of 
expired halofantrine by 
2 years  
Ndomondo-
Sigonda (2005) 
         
Quinine Angola PQ   tab CR 1/2 failed dissolution 
tests 
Gaudiano et al. 
(2007) 
Quinine Burkina Faso PQ   tab C 3/9 samples failed 
chemical assays 
Tipke et al. 
(2008) 
Quinine Burundi F   tab CR 1/3 (30%) failed 
content assay. 
Contained chloroquine 
Gaudiano et al. 
(2007) 
Quinine Cameroon F   tab and 
injection 
C 1/24 (4%) no quinine  
detected (tablet) 
WHO (1995) 
Quinine Cameroon F   tab C 2/4 (50%) of patients 
who had taken 




Quinine Cameroon F, PQ   tab C 7/70 (10%) contained 
no API; 45/70 (64%) 
probably PQ 
Basco (2004) 
Quinine Chad GQ   tab and 
injection 
C 6/6 passed all tests WHO  (1995) 
Quinine 300mg DR Congo PQ   tab CR 88.6% quinine present Gaudiano et al. 
(2006) 
Quinine DR Congo PQ   tab CR 1/10 (10%) failed 
uniformity of mass 
assay, 3/10 (30%) 
failed dissolution tests 
and 1/10 (10%) failed 
content assay. Total 
failures were 4/10 
(40%) 
Gaudiano et al. 
(2007) 
Quinine sulphate Ghana F   ? S Stated to be counterfeit Ghana News 
Agency (2010) 
Quinine Kenya PQ   Raw material, 
tabs, syrup & 
injection 
C ½ raw material failed, 
2/2 tablets, 1/1 syrups 
and 1/1 injections 
passed 
Thoithi et al. 
(2002) 
Quinine Madagascar S   tab or 
injection 
C 1/11 (9%) ‘défauts de 
fabrication’ 
WHO (1995) 
Quinine sulphate Nigeria F   tab Bio sugar-coated 
tablets with no quinine 








Nigeria GQ   injection R 10/10 passed British 
Pharmacopeia limits 
Taylor et al. 
(2001) 
Quinine sulphate Nigeria PQ   syrup 
tab 
R 1/1 & 4/17 (24%) failed 
British Pharmacopeia 
limits 
Taylor et al. 
(2001) 
Quinine Nigeria F   tab R 13/28 (46%) failed 





Quinine Rwanda F    CR Fake ‘quinine is in the 
form of yellow-coated 
tablets in a white 
cylindrical plastic tin 
with the tablets being 




Quinine Sudan PQ   injection CR Some failed due to 
change in colour 
Alfadl et al. 
(2006) 
Quinine Sudan GQ   tab CR All samples (≥50 ) 
passed assays 
Alfadl et al. 
(2006) 
Quinine Tanzania F  ‘company in 
Cyprus’ 
injection CR 2001, expired 
chloroquine injection 
(from an unregistered 
Indian company) was 
relabeled as Quinine 
Dihydrochloride 
Injection 600mg/2ml 




Quinine Tanzania F   tab CR 2005, No API detected Ndomondo-
Sigonda (2005) 
Quinine Tanzania PQ   tab R 15/63 failed chemical 
tests 
Kaur et al. 
(2008) 
Quinine salts Tanzania PQ    C 2/81 (2%) failed tests at 
Quality Control 
Laboratory during one 
year 
Risha et al. 
(2008) 
Quinine Uganda F  ‘Kampala 
Pharmaceutical 
Industries’ 
tab CR Counterfeit packaging, 
no API detected 
Bogere & 
Nafula (2007) 
Quinine Uganda F   tab CR Tin of ‘magnesium’ 
relabelled as quinine 
Mugabe (2009) 
Quinine Uganda F   tab CR Chloroquine relabelled 
as quinine 
Mugabe (2009) 
         
Mefloquine Angola GQ   tab CR 2/2 passed API content  
assays 
Gaudiano et al. 
(2007) 
Mefloquine Ghana GQ   tab C 0/1 failed TLC and/or 
dissolution tests 
Bate et al. 
(2008) 
Mefloquine Nigeria PQ    C 1/2 (50%) failed TLC 
and/or dissolution 
Bate et al. 
(2008) 
Mefloquine Senegal ? PQ   tab CR Failed prophylaxis. 




Mefloquine Sudan GQ   tab CR Passed assays Alfadl et al. 
(2006) 
Mefloquine Tanzania GQ    C 0/3 failed TLC and/or 
dissolution tests 
Bate et al. 
(2008) 
Mefloquine Uganda PQ 
 
   C 3/11 (27%) failed TLC 
and/or dissolution tests 
Bate et al. 
(2008) 
         
Sulphadoxine-
pyrimethamine 


















Cameroon PQ  ‘Ajanta Pharma 
Limited, Mauritius’ 















tab r Tablets chipped.  
Pyrimethamine 87.2% 
API. Pyrimethamine 




Cameroon PQ  ‘Swiss Pharma 
Nigeria Ltd, 
Nigeria’ 





Congo PQ   tab CR 6/10 (60%) failed 
dissolution tests 











F ‘Maloxine’ ‘Encore 
Pharmaceuticals 
India’ 
tab C Contains 102.5% stated 
dose of sulphadoxine 
and 85.9% stated dose 
of pyrimethamine. 
Copy of packaging and 







F  ‘Brown & Burk 
Pharmaceutical Ltd. 
India 
tab C Copy of packaging and 
false information on 
origin given. Contains 






F  ‘Sarvodaya 
Laboratories, India 
tab C Copy of packaging and 
false information on 
origin given. Contains 






F  ‘India’ tab C Copy of packaging and 
false information on 
origin given. Contains 






F ‘Melaxime’ ‘Syncom 
Formulations, 
India’ 
tab C Copy of packaging. 
Contains correct 









Ghana PQ   tab C 3/8 (37.5%) failed 
content assays & ¾ 
(75%) failed 
dissolution tests 
WHO  (2003) 
Sulphadoxine-
pyrimethamine 
Ghana PQ   tab C 3/6 (50%) failed TLC 
and/or dissolution tests 




Ghana PQ  ‘Ally Pharma 
Options, India’ 
tab r Pyrimethamine failed 
dissolution tests. 




Ghana PQ  ‘Kinapharma Ltd, 
Ghana’ 
tab r Pyrimethamine 83.9% 
API.  Pyrimethamine 




Ghana PQ  ‘Mission 
Pharmaceuticals 
Ltd, India’ 





Ghana PQ  ‘Phyto-Riker 
Pharmaceuticals 
Ltd, Ghana’ 















Switzerland’ and  
‘Cosmos Industries, 
Nairobi, Kenya’ 
tab Bio No significant 
difference in 
bioavailability  




Kenya GQ   tab C All 3 samples passed 
assays 














Kenya PQ   tab & 
suspension 
C 15/39 (38%) tablet 
samples failed and 2/3  
(67%) suspensions 
failed content assays 




Kenya PQ   tab C 0/12 failed content 
assays & 11/12 (91.7%) 
failed dissolution tests 
WHO  (2003) 
Sulphadoxine- 
pyrimethamine 
Kenya PQ   tab 
syrup 
R 13/37 (35%) tablet 
samples & 16/27 (59%) 
syrup failed content 
and/or dissolution test 




Kenya PQ   tab C 6/16 (38%) failed TLC 
and/or dissolution tests 




Madagascar GQ   tab C 5/5 passed all tests WHO (1995) 
Sulphadoxine- 
pyrimethamine 










Mali PQ   tab C 0/7 failed content 
assays & 7/7 (100%) 




Mozambique PQ   tab C 1/18 (5.5%) failed 











ten Ham (1992) 
Sulphadoxine- 
pyrimethamine 
Nigeria PQ   tab 
syrup 
 




(23%) syrups failed  
pyrimethamine and 
5/13 (38%) failed 
sulphadoxine by British 
Pharmacopeia for API 
% content 




Nigeria S   tab C 5/8 (63%) brands (all 
labelled as made in 
India) failed friability 
tests, dissolution tests 
or  API % content 
assays 




Nigeria F ‘Fansidar’  tab CR Paracetamol tablets 




Nigeria F ‘Fansidar’ 
‘Maloxine’ 
 tab CR Seizure of fake labels Edike (2003) 
Sulphadoxine-
pyrimethamine 






Nigeria PQ   tab C 1/2 (50%) failed TLC 
and/or dissolution tests 




Nigeria F ‘Maloxine’   CR 348,000 tablets in 
sachets of three tablets 
each, contained in 
6,960 boxes packed in 
960 cartons with Batch 
No: EM-396 and 
manufacturing and 
expiring dates 04/2008 
and 03/2011. In 
container, shipped from 






Nigeria F ‘Amalar’  tab CR 294,000 sachets of 
‘Amalar’ packed as 
three tablets each, 
contained in 5,880 
boxes packed in 196 
cartons with Batch No: 
ARTP 0053 and 
manufacturing and 
expiring dates of 
January 2007 and 
January 2010 
respectively. In 
container, shipped from 






Nigeria PQ   tab R 44/113 (39%) failed 
API% HPLC assays 





Nigeria PQ  ‘Bond Chemical 
Ind. Ltd, Nigeria’ 
tab r Pyrimethamine 88.6% 
API.  Pyrimethamine 




Nigeria PQ  ‘Emzor Pharm Ind. 
Ltd, Nigeria’ 
tab r 4/4 (100%) 
pyrimethamine failed 
dissolution tests. 1/4 
(25%) sulphadoxine 
failed dissolution tests,   
2/4 (50%) uniformity 




Nigeria PQ  ‘Evans Medical Plc, 
Nigeria’ 
tab r Sulphadoxine  & 
pyrimethamine failed 
dissolution. Uniformity 




Nigeria PQ  ‘May & Baker 
Nigeria Plc, 
Nigeria’ 






Nigeria PQ  ‘Medrel 
Pharmaceuticals 
Ltd, India’ 














Nigeria C  ‘Shreechem Lab, 
India’ 




dissolution tests.  
Tablets mottled. 
Tablets differed from 





Nigeria PQ  ‘Shreechem Lab, 
India’ 





Nigeria PQ  ‘Swiss Pharma 
Nigeria Ltd, 
Nigeria’ 






Nigeria PQ  ‘VITAPHOS 
Laboratory Nigeria 
Ltd, Nigeria’ 
tab r Pyrimethamine 80.2% 






Rwanda S  ‘Labophar, Butare, 
Rwanda’ 
tab C Failed pyrimethamine 
release requirement on 
dissolution testing 




Rwanda PQ   tab C 3/6 (50%) failed TLC 
and/or dissolution tests 




Senegal PQ   tab C 55% failed 
monograph tests 














Sierra Leone F  ‘Roche’ tab CR Counterfeit Sesay (1988) 
Sulphadoxine- 
pyrimethamine 
Sudan PQ   tab C 0/20 failed content 
assays & 12/15 (80%) 




Tanzania S   tab C All 9 brands passed 
content assay. 4/9 
(44%) brands failed 
dissolution assays 













tab C 2/4 (50%) did not meet 
tolerance limits for 
dissolution tests 












tab C 2/18 (11%) & 8/18 
(44%) samples failed 
the assay for content 
and dissolution tests, 
respectively 













tab C 4/11 (36%) brands 
failed hardness, 
friability or 
disintegration tests. All 
contained an impurity, 
closely related 
to sulphadoxine at ~ 
0.5% w⁄w. 






‘Tanzania’ tab Bio Inferior bioavailability 
in comparison to 
Fansidar 




Tanzania PQ   tab R 8/58 failed chemical 
tests 




Tanzania PQ   tab C 3/11 (27%) failed TLC 
and/or dissolution tests 




Tanzania PQ   tab C 39/258 (15%) failed 
tests at Quality Control 
Laboratory during one 
year 




Tanzania PQ  ‘Shely’s 
Pharmaceuticals 
Ltd, Tanzania’ 





Tanzania PQ  ‘Shely’s 
Pharmaceuticals 
Ltd, Tanzania’ 





To Togo via 
Belgium  
F ‘Fansidar’ ‘Roche’ tab CR In transit from 





Uganda PQ   tab C 3/9 (33%) failed TLC 
and/or dissolution tests 




Uganda PQ ‘Agosidar’, 
‘L-Kelfin’, 
‘Malagon’ 
 tab r 7/43 (16%) failed 
dissolution tests and 









Zimbabwe PQ   tab C 1/10 (10%) failed 









F ‘Metakelfin’ ‘Pharmacia’ oral CR White sachets 
withdrawn and replaced 
by packaging of silver 






Ghana F ‘Metakelfin’ ‘Pharmacia & 
Upjohn’ 




Kenya PQ   tab & ‘drops’ C 1/1 tablet sample 
passed and 1/2 ‘drops’ 
failed content assay 









Nigeria PQ  ‘Drugfield 
Pharmaceuticals 
Ltd, Nigeria’ 
tab r 1/1 pyrimethamine 




Tanzania F ‘Metakelfin’ ‘Pharmacia and 
Upjohn’ 
‘Farmitalia’ 










sulfalene. Batch E894A 
(10/2008-01/2012) 
detected, 75.6% 
sulfalene. Fake blister 
shining (rather than 
‘dim’) silver with 
instructions in English 
& French (rather than 
only English) with 






Tanzania PQ   tab R 9/42 failed API % 
HPLC assays and 
dissolution tests 











Tanzania PQ  ‘Shely’s 
Pharmaceuticals 
Ltd, Tanzania’ 





Uganda F ‘Metakelfin’  tab CR fake Mugabe (2009) 
         
Tetracycline Cameroon GQ   tab C 13/13 passed HPLC 
API% assays and mass 
uniformity tests 
WHO (1995) 
Tetracycline Chad GQ   tab C 4/4 passed HPLC 
API% assays and mass 
uniformity tests 
WHO (1995) 
Tetracycline Madagascar GQ   tab C 8/8 passed HPLC 
API% assays and mass 
uniformity tests 
WHO (1995) 
Tetracycline Nigeria PQ   caps C 1/10 failed British 
Pharmacopeia  HPLC 
API% assays 
Shakoor et al. 
(1997) 
Tetracycline Nigeria F    CR Relabelled expired 
drugs 
Erhun et al. 
(2001) 
         
Doxycycline Nigeria PQ   caps R 6/19 (68%) failed 
British Pharmacopeia 
HPLC API% assays 
Taylor et al. 
(2001) 
         
Proguanil Nigeria GQ   tab R 19/19 passed British 
Pharmacopeia HPLC 
API% assays 
Taylor et al. 
(2001) 





Accra, Ghana GQ, 
PQ 
  tab r 2007 5/13 (38%),  
2010 5/23 (22%) failed 
Minilab tests 
 
2007 1/13 (8%), 2010 
2/23 (9%) failed visual 
inspection 










  tab r 2007 3/8 (38%),  
2008 8/59 (14%),  
2010 5/30 (17%) failed 
Minilab tests 
 
2007 1/8 (13%), 2008 
3/59 (51%), 2010 4/30 
(13%) failed visual 
inspection 
Bate & Hess 
(2010) 
         
Artemisinin monotherapies and ACTs 
         
Artesunate Burkina Faso PQ, 
(S or 
D ?) 
  tab C 1/9 artesunate samples 
in poor physical 
condition 
Tipke et al. 
(2008) 
Artesunate  Cameroon F ‘Arsuman’ ‘Sanofi-
synathelabo’ 
tab CR Copy of ‘Arsumax’. 
Contained correct 
API% (50mg/tablet) by 
HPLC 
Newton et al. 
(2006b) 
Artesunate Chad F   tab CR Counterfeit Aline Plançon 
pers. obs 
Artesunate 100mg DR Congo F ‘Saphnate’ ‘Saphire sprl’ 
‘Belgium’ 
tab C Contained 98.9% API.  
Stated manufacturer 
‘Saphire sprl’’ does not 




Artesunate Ghana S   tab C 14 of 17 (82.4%) 
sampled artesunate 
tablets sold in 
pharmacies in Kumasi 




et al. (2008) 
 
Artesunate Ghana PQ   tab C 3/8 (38%) failed TLC 
and/or dissolution tests 
Bate et al. 
(2008) 
Artesunate Ghana F ‘Artesunate’ ‘Guilin 
Pharmaceuticals 
Co. Ltd’ 
tab CR Counterfeit packaging Ghana News 
Agency (2011) 
Artesunate Kenya PQ ‘Gsunate 
Forte’ 
‘GVS’ tab C Contained 88.5% API Atemnkeng et 
al. (2007) 
Artesunate Kenya PQ   tab C 0/0 failed TLC and/or 
dissolution tests 
Bate et al. 
(2008) 
Artesunate Nigeria F   tab S Smuggled in handbags Oyeniran (2006) 
 
Artesunate Nigeria F   tab S Smuggled amongst 





Artesunate Nigeria PQ   tab Bio 1/9 (11%) brands failed 
dissolution tests 
Esimone et al. 
(2008a) 
Artesunate Nigeria S  Failed brands were 
labelled as from 
‘India, Vietnam, 
Nigeria and China’ 
tab C 5/9 (56%) brands failed  
UV spectroscopic 
assays  
Esimone et al. 
(2008b) 
Artesunate Nigeria PQ   tab C 2/6 (33%) failed TLC 
and/or dissolution tests 
Bate et al. 
(2008) 
Artesunate Nigeria GQ   tab C 0/24 failed API% 
content HPLC assays 
or dissolution tests 
Onwujekwe et 
al. (2009) 
Artesunate Nigeria PQ   tab R 2/15 contained <50% 
API 
Odunfa et al. 
(2009) 
Artesunate Nigeria F ‘Artesunat’  tab S Imported from Hong 
Kong  
Udoh (2010b) 
Artesunate Tanzania PQ   tab C 4/13 (31%) failed TLC 
and/or dissolution 
Bate et al. 
(2008) 
Artesunate Tanzania GQ    C 0/22 failed tests at 
Quality Control 
Laboratory during one 
year 
Risha et al. 
(2008) 
Artesunate Uganda PQ   tab C 6/18 (33%) failed TLC 
and/or dissolution tests 
Bate et al. 
(2008) 
         
Artemether 50mg DR Congo F ‘Artesaph’ ‘Saphire sprl’ 
Belgium 
tab C Contained 100.6% API. 
Stated manufacturer 
‘Saphire sprl’’ does not 




Artemether Ghana PQ   tab C 0/3 failed TLC and/or 
dissolution tests 
Bate et al. 
(2008) 
Artemether 150mg Kenya PQ ‘Emal’ ‘Themis’ Im C Contained 77% API Atemnkeng et 
al. (2007) 
Artemether Kenya PQ   tab C 1/1 (100%) failed TLC 
and/or dissolution tests 
Bate et al. 
(2008) 
Artemether Sudan GQ   inj CR Passed assays Alfadl et al. 
(2006) 
Artemether Uganda PQ   tab C 2/7 (29%) failed TLC 
and/or dissolution tests 
Bate et al. 
(2008) 




DR Congo F ‘Salaxin’ ‘Saphire sprl’ 
Belgium 
tab C Contained 87.7% API. 
Stated manufacturer 
‘Saphire sprl’’ does not 
exist in Belgium at 





Ghana PQ   tab C 2/5 (40%) failed TLC 
and/or dissolution tests 




Kenya F ‘Cotecxin’ ‘Beijing COTEC 
New Technology 
Corp’ 






Kenya F ‘Cotecxin’ ‘Beijing COTEC 
New  Technology 
Corp’ 


















Kenya PQ   tab C 5/9 (56%) failed TLC 
and/or dissolution tests 




Nigeria PQ   tab C 1/1 (100%) failed TLC 
and/or dissolution tests 




Nigeria F   tab CR 1/4 (25%) no API 
detected 
Onwujekwe et 
al. (2009), Ioset 
& Kaur (2009) 
Dihydroartemisinin 
 
Tanzania PQ   tab C 2/4 (50%) failed TLC 
and/or dissolution tests 




Tanzania F ‘Cotecxin’ ‘Beijing COTEC 
New Technology 
Corp’ 
tab CR No API detected Arrow (2001) 
Dihydroartemisinin 
 
Uganda PQ   tab C 2/3 (67%) failed TLC 
and/or dissolution tests 




Accra, Ghana GQ, 
PQ 
  tab r 2007 5/16 (31%), 2010 
5/23 (22%) failed 
Minilab tests 
 
2007 2/16 (13%), 2010 
4/24 (17%) failed 
visual inspection 








  tab r 2007 3/7 (43%), 2008 
12/65  (18%), 2010 
6/47 (13%) failed 
Minilab tests 
 
2007 1/7 (14%), 2008 
9/65 (14%), 2010 3/47 
(6%) failed visual 
inspection 
Bate & Hess 
(2010) 
         
Artemether-
lumefantrine 
Burkina Faso GQ   tab C 0/4 failed Minilab 
assays 




Cameroon PQ 20/120 ‘Ajanta Pharma 
Ltd., India  
tab r Tablets mottled, 
artemether 82%API. 







  tab C 3/8 (38%) failed TLC 
and/or dissolution tests 









Ghana PQ 20/120 ‘Jiangsu Yixing 
Forward Pharm 
Factory, China’ 






Ghana PQ 20/120 ‘Medreich PLC, 
India’ 








  tab C 0/4 failed TLC and/or 
dissolution tests 




Kenya PQ 20/120 ‘Novartis 
Pharmaceuticals 
Corporation, USA’ 






Madagascar PQ ‘Artefan’  tab r 1/1 failed USP %API 





Nigeria PQ   tab C 1/7 (14%) failed TLC 
and/or dissolution tests 




Nigeria F ‘Lonart-DS’ 
 
‘Bliss GVS Pharma 
Limited’ 
tab S 60,000 tablets hidden in 
bangs, shoes and 
blankets, valued at N10 
million, seized at Lagos 
International Airport. 





Nigeria F ‘Lonart-DS 
80/400’ 





Nigeria F ‘Persidon 
20/120’ 












Nigeria PQ 20/120 ‘Ecomed Pharma 
Ltd., Nigeria’ 






Nigeria PQ 20/120 ‘Jiangsu Yixing 
Forward Pharm 
Factory, China’ 
tab r Tablets with spots, 
artemether 89.7% API 





Nigeria PQ 20/120 ‘Jiangsu Yixing 
Forward Pharm 
Factory, China’ 





Nigeria PQ 20/120 ‘Jiangsu Yixing 
Forward Pharm 
Factory, China’ 
tab r Artemether 85.5% API, 
lumefantrine 71.0% 
API. Failed dissolution 




Nigeria PQ 20/120 ‘Jiangsu Yixing 
Forward Pharm 
Factory, China’ 






Nigeria PQ 20/120 ‘Macleods 
pharmaceuticals 
Ltd.’ 









Nigeria PQ 40/240 ‘May & Baker 
Nigeria PLC’ 
















Nigeria PQ 20/120 ‘Naxpar Lab Ltd, 
India’ 





Nigeria PQ 20/120 ‘Naxpar Lab Ltd, 
India’ 
tab r Artemether 29.0% API, 
lumefantrine 81.5% 
API. Failed uniformity 









  tab C 0/3 failed TLC and/or 
dissolution tests 




Senegal PQ ‘Artefan’  tab r 3/3 failed USP %API 







  tab C 0/1 failed TLC and/or 
dissolution tests 




Uganda PQ   tab C 2/9 (22%) failed TLC 
and/or dissolution tests 




Uganda PQ ‘Artefan’  tab r 4/11 failed USP %API 
assay and/or dissolution 
testing 
USP (2009a) 




Cameroon PQ 100/300 ‘Adams 
Pharmaceuticals 
(ANHUI) Co Ltd, 
China’ 




Cameroon PQ 100/300 ‘Adams 
Pharmaceuticals 
(ANHUI) Co Ltd, 
China’ 
 






Cameroon PQ 100/300 ‘Adams 
Pharmaceuticals 
(ANHUI) Co Ltd, 
China’ 







Cameroon PQ 10/153.1 ‘Plethico 
Pharmaceuticals 
Ltd, India’ 






Ghana PQ 100/300 ‘Atlantic 
Pharmaceutical Ltd, 
Ghana’ 










Ghana PQ 50/153.1 ‘Bliss GVS Pharma 
Ltd, India’ 










tab r Artesunate related 
substances elevated. 
Artesunate uniformity 





Ghana PQ 50/153.1 ‘Ipca Laboratories 
Ltd, India’ 
tab r Artesunate uniformity 





Kenya PQ 50/150 ‘Cosmos Ltd, 
Kenya’ 






Madagascar PQ ‘Amosunate’  tab r 2/2 failed USP %API 






Madagascar PQ ‘Falcimon’  tab r 1/4 failed USP %API 






Nigeria PQ 200/600 ‘Adams 
Pharmaceutical 
(ANHUI) Co Ltd, 
China’ 











Nigeria PQ 50/150 ‘Adams 
Pharmaceutical 
(ANHUI) Co Ltd, 
China’ 
powder r Artesunate related 
substances elevated. 





Nigeria PQ 100/300 ‘Baader Schulz 
Lab, India’ 
tab r Artesunate related 
substances elevated. 
Amodiaquine 






Nigeria PQ 50/153.1 ‘Baader Schulz 
Lab, India’ 
tab r Amodiaquine 115% 
API. Artesunate related 
substances elevated. 
Artesunate uniformity 
of mass non-compliant. 





Nigeria PQ 50/150 ‘Madras 
Pharmaceuticals, 
India’ 
tab r Artesunate related 
substances elevated.  




Nigeria PQ 50/150 ‘Madras 
Pharmaceuticals, 
India’ 
tab r Artesunate related 
substances elevated.  





Nigeria PQ 50/153.1 ‘Saga Laboratories 
Ltd, India’ 









Nigeria PQ 50/153.1 ‘Saga Laboratories 
Ltd, India’ 








Nigeria PQ 50/200 ‘Swiss Pharma 
Nigeria Ltd, 
Nigeria’ 
tab r Artesunate related 
substances elevated. 





Senegal PQ ‘Camoquin’  tab r 2/2 failed USP %API 






Senegal PQ ‘Falcimon’  tab r 4/15 (27%) failed USP 






Senegal PQ ‘Larimal’  tab r 1/1 failed USP %API 






Uganda PQ ‘Duact’  tab r 2/2 failed USP %API 






Uganda PQ ‘Larimal’  tab r 5/5 failed USP %API 
assay and/or dissolution 
tests 
USP (2009a) 




Cameroon PQ 50/200 ‘Kamala Overseas, 
India’ 







Cameroon PQ 50/200 ‘Kamala Overseas, 
India’ 







Cameroon PQ 50/200 ‘Kamala Overseas, 
India’ 
tab r Artesunate 72.4% API. 





Madagascar PQ ‘Coasucam’  tab r 1/11 (9%) failed USP 






Nigeria PQ 100/306.2 ‘Emzor Pharma 
Ind. Ltd, Nigeria’ 
caplet r Artesunate 87.2% API. 





Nigeria PQ 100/306.2 ‘Emzor Pharma 
Ind. Ltd, Nigeria’ 
caplet r Artesunate failed 
dissolution tests. 





Nigeria PQ 100/306.2 ‘Emzor Pharma 
Ind. Ltd, Nigeria’ 
caplet r Artesunate 82.5% API. 





Nigeria PQ 50/150 ‘Emzor Pharma 
Ind. Ltd, Nigeria’ 
caplet r Artesunate 87.8% API. 





Nigeria PQ 200/600 ‘Mercury 
Laboratories Ltd, 
India’ 






Nigeria PQ 50/150 ‘Rajat Pharmachem 
Ltd, India’ 
powder r Amodiaquine 76.4% 
API. Contaminant on 
TLC 
WHO (2011) 





Senegal PQ ‘Co-arinate’  tab r 1/3 (33%) failed USP 
%API assay and/or 
dissolution tests 
USP (2009a) 




Senegal PQ ‘Artequin’  tab r 3/3 failed USP %API 















         
ACTs Accra, Ghana GQ, 
PQ 
  tab r 2007 3/8 (38%), 2010 
1/10 (10%) failed 
Minilab tests 
2007 1/8 (13%), 2010 
0/10 (0%) failed visual 
inspection 






  tab r 2007 1/7 (14%), 2008 
1/5 (20%), 1/17 (6%) 
failed Minilab tests 
 
2007 1/7 (14%), 2008 
0/5 (0%), 2010 0/17 
(0%) failed visual 
inspection 
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